BeiGene, Ltd. (BGNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
BGNE POWR Grades
- BGNE scores best on the Value dimension, with a Value rank ahead of 70.41% of US stocks.
- BGNE's strongest trending metric is Quality; it's been moving down over the last 179 days.
- BGNE ranks lowest in Momentum; there it ranks in the 4th percentile.
BGNE Stock Summary
- With a market capitalization of $21,330,946,597, BeiGene Ltd has a greater market value than 88.24% of US stocks.
- BGNE's price/sales ratio is 18.13; that's higher than the P/S ratio of 92.21% of US stocks.
- As for revenue growth, note that BGNE's revenue has grown 280.83% over the past 12 months; that beats the revenue growth of 97.02% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to BeiGene Ltd, a group of peers worth examining would be QRVO, SGEN, BLDP, RDCM, and CYTK.
- Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.
BGNE Valuation Summary
- In comparison to the median Healthcare stock, BGNE's EV/EBIT ratio is 171.33% lower, now standing at -20.9.
- BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
- BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
Below are key valuation metrics over time for BGNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BGNE | 2021-08-31 | 30.3 | 8.0 | -21.9 | -20.9 |
| BGNE | 2021-08-30 | 29.7 | 7.8 | -21.4 | -20.5 |
| BGNE | 2021-08-27 | 27.7 | 7.3 | -20.0 | -19.1 |
| BGNE | 2021-08-26 | 27.8 | 7.3 | -20.1 | -19.1 |
| BGNE | 2021-08-25 | 28.5 | 7.5 | -20.6 | -19.6 |
| BGNE | 2021-08-24 | 28.1 | 7.4 | -20.3 | -19.3 |
BGNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
- BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
- AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.
The table below shows BGNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.168 | 0.883 | -0.377 |
| 2021-03-31 | 0.165 | 0.897 | -0.358 |
| 2020-12-31 | 0.065 | 0.771 | -0.552 |
| 2020-09-30 | 0.070 | 0.746 | -0.678 |
| 2020-06-30 | 0.078 | 0.704 | -0.890 |
| 2020-03-31 | 0.166 | 0.826 | -0.893 |
BGNE Stock Price Chart Interactive Chart >
BGNE Price/Volume Stats
| Current price | $202.24 | 52-week high | $426.56 |
| Prev. close | $194.47 | 52-week low | $118.18 |
| Day low | $197.34 | Volume | 317,200 |
| Day high | $205.83 | Avg. volume | 306,710 |
| 50-day MA | $164.34 | Dividend yield | N/A |
| 200-day MA | $220.63 | Market Cap | 20.93B |
BeiGene, Ltd. (BGNE) Company Bio
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.
Latest BGNE News From Around the Web
Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
BeiGene''s Brukinsa Applications Under FDA, European Review For LeukemiaThe European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its |
BeiGene''s Brukinsa gets FDA review for expanded use in blood cancer subtypeThe U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic |
BeiGene's Brukinsa Applications Under FDA, European Review For LeukemiaThe European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. Additionally, the FDA has als |
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone LymphomaBASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyt |
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic LeukemiaCAMBRIDGE, Mass. and BEIJING, February 22, 2022--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia |
BGNE Price Returns
| 1-mo | 7.15% |
| 3-mo | 66.99% |
| 6-mo | -8.01% |
| 1-year | -36.64% |
| 3-year | 52.08% |
| 5-year | 178.41% |
| YTD | -25.35% |
| 2021 | 4.85% |
| 2020 | 55.88% |
| 2019 | 18.18% |
| 2018 | 43.53% |
| 2017 | 221.87% |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...